24 de Septiembre del 2019
On September 23, 2019, Sandoz, Inc. announced a voluntary recall of Ranitidine 150mg capsules, and 300mg capsules due to an elevated amount of an unexpected impurity (NDMA) found in the active pharmaceutical ingredient.
The FDA recommends patients to continue to take their medication and speak to their physician or pharmacist on alternate healthcare treatment options.
Additional information is available on the FDA's website.
Última actualización: 08 de Diciembre del 2023